PCSK9 and type 2 diabetes mellitus: In conclusion, we unravelled, in patients with T2DM in good glycemic control, already treated with the state-of-the-art strategies for CV prevention (100% on ASA, 55% on statins, 85% antihypertensives), an inverse correlation between circulating PCSK9 and early EPC number, with those on statins showing the highest PCSK9 levels paralleled by the most impaired EPC number.